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http:WHAT THIS PAPER ADDS
A complex relationship was found between body mass index (BMI) and long-term outcomes in patients with
critical limb ischemia (CLI) after endovascular treatment of isolated infrapopliteal artery lesions. The 3 year
overall survival rates were 33.3%, 61.2%, and 69.8% in underweight, normal, and overweight/obese patients,
respectively. The survival rate was signiﬁcantly lower in underweight patients and signiﬁcantly higher in over-
weight/obese patients compared with patients of normal weight. Although underweight patients with CLI have
a poor prognosis because of comorbidities, low BMI itself is an independent predictor of a poor prognosis in
patients with CLI.Objective: To investigate the relationship between body mass index (BMI) and long-term outcomes of patients
with CLI after endovascular treatment (EVT).
Design: Retrospective multicenter study.
Subjects: 1088 consecutive patients (1306 limbs, mean age 72  10 years) with CLI who underwent EVT for
isolated infrapopliteal artery lesions were evaluated. These subjects were identiﬁed in the J-BEAT III registry.
Methods: The patients were divided into groups based on BMI <18.5 kg/m2 (underweight, n ¼ 188; 219 limbs),
18.5 to 24.9 kg/m2 (normal weight, n ¼ 718; 868 limbs), and >25.0 kg/m2 (overweight/obese, n ¼ 182; 219
limbs). The endpoints were overall survival and freedom from major adverse limb events (MALE).
Results: The median follow up period was 1.5 years (range: 1 monthe8.7 years). The 3 year overall survival rates
were 33.3%, 61.2%, and 69.8% in underweight, normal, and overweight/obese patients, respectively. The survival
rate was signiﬁcantly lower in underweight patients and signiﬁcantly higher in overweight/obese patients
compared with patients of normal weight (both p < .0001). The 3 year rates of freedom from MALE did not differ
signiﬁcantly among the three groups (36.4%, 45.4%, and 52.3%, respectively, p ¼ .32). Age, BMI <18.5 kg/m2,
heart failure, aortic valve stenosis, renal failure, triglyceride levels, serum albumin <3.0 g/dL, anticoagulant
treatment, non-ambulatory status, and Rutherford 6 classiﬁcation all were signiﬁcantly associated with overall
survival.
Conclusions: BMI has a complex correlation with mortality in patients with CLI after EVT for isolated
infrapopliteal artery lesions. Underweight patients with CLI have an extremely poor prognosis. Such patients have
many other factors associated with mortality, but low BMI was identiﬁed as an independent predictor of a poor
prognosis in patients with CLI. Similarly, normal weight patients had a small but signiﬁcant increase in mortality
compared with overweight/obese patients.
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The “obesity paradox” emerges from the observation that
mortality in patients with hypertension, heart failure,1,2
and coronary artery disease3 decreases as their body
mass index (BMI) increases, despite the association of
obesity with cardiovascular risk factors. BMI has also been
found to be inversely related to mortality in patients with
298 N. Murata et al.peripheral artery disease (PAD).4,5 However, most patients
in these reports presented with claudication alone,
whereas patients with critical limb ischemia (CLI) are
known to suffer a higher mortality (50e60% at 5 years)
compared with those with uncomplicated claudication
(20e30% at 5 years).6
In vascular surgery, an inverse relationship between
obesity and mortality has been proposed in patients with
CLI requiring lower extremity revascularization or amputa-
tion,7,8 but this relationship is unclear in patients with CLI
after endovascular treatment (EVT) as the primary therapy.
EVT is now an alternative ﬁrst line treatment for patients
with CLI because its long-term outcome has been proven
non-inferior to that of surgery.9,10 EVT is also employed in
inoperable cases because of age, comorbidities, and general
condition. The purpose of this study was to investigate the
relationship between BMI and long-term outcomes in pa-
tients with CLI following EVT.SUBJECTS AND METHODS
Study design and population
The J-BEAT (Japanese Below the knee Artery Treatment
Trial) III registry is a physician initiated, non-commercial,
multicenter registry of consecutive patients with CLI un-
dergoing EVT for isolated infrapopliteal artery lesions be-
tween April 2004 and March 2012 in Japan. A total of
1091 consecutive patients (1310 limbs) were identiﬁed
retrospectively, with subsequent exclusion of three pa-
tients (four limbs) with no data for BMI. The patients
were divided into three groups based on BMI as recom-
mended by the World Health Organization (Fig. 1):
<18.5 kg/m2 (underweight, 188 patients, 219 limbs), 18.5
to 24.9 kg/m2 (normal weight, 718 patients, 868 limbs),Figure 1. Patient ﬂow charts. A total of 1091 consecutive patients (
infrapopliteal artery lesions were identiﬁed retrospectively. Three pati
mass index (BMI). The patients were divided into three groups based on
24.9 kg/m2 (normal weight, 718 patients, 868 limbs), and >25.0 kg/mand >25.0 kg/m2 (overweight/obese, 182 patients, 219
limbs). Weights and heights were measured at the time of
admission.
Independent researchers collected demographic, angio-
graphic, and procedural data from hospital charts or hos-
pital databases according to pre-speciﬁed deﬁnitions.
Follow up data were obtained from hospital charts or by
contacting patients or referring physicians. The relevant
review boards or ethics committees in all participating
centers approved the study protocol. Written informed
consent was obtained from each patient. This study is
registered with the University Hospital Medical Information
Network-Clinical Trial Registry (UMIN-CTR), as accepted by
the International Committee of Medical Journal Editors (No.
UMIN 000004917).Endovascular intervention and follow up protocol
The EVT strategy was limited to the use of balloon an-
gioplasty (without stenting), which was the only strategy
permitted in Japan at the time of the study. Balloon an-
gioplasty was performed with repeated dilation of each
vessel by inﬂating optimally sized balloons for 1e3 min at
nominal pressure. Satisfactory results were deﬁned as
persistent stenosis of <50% on angiography and
achievement of one straight vascular route to the wound.
Antiplatelet agents were administered prior to EVT and
continued lifelong. Each patient was evaluated at 1, 3, and
6 months after EVT and then every 6 months after that.
Repeat revascularization was performed when indicated
by reappearance of symptoms with Rutherford11 category
4, 5, or 6 and ﬁndings of ischemia with signiﬁcant
reduction of ankle-brachial index (ABI) or skin perfusion
pressure.1310 limbs) who underwent endovascular treatment for isolated
ents (4 limbs) were excluded because they had no data for body
BMI <18.5 kg/m2 (underweight, 188 patients, 219 limbs), 18.5 to
2 (overweight/obese, 182 patients, 219 limbs).
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The primary endpoint was overall survival. The secondary
endpoint was freedom from major adverse limb events
(MALE). Data from patients with normal BMI were used as a
reference for comparison of mortality and freedom from
MALE with those in the underweight and overweight/obese
groups.
Deﬁnitions
CLI was deﬁned as Rutherford category 4, 5, or 6. Isolated
infrapopliteal artery lesions were detected by digital sub-
traction angiography. Patients with iliofemoral lesions with
signiﬁcant stenosis (>75% by angiography) or chronic total
occlusion were excluded. MALE were deﬁned as above the
ankle amputation or any repeat revascularization of the
index limb. Hypertension was deﬁned as requiring treat-
ment with oral antihypertensive agents or as systolic blood
pressure >140 mmHg. Dyslipidemia was deﬁned as
requiring treatment with statins or a low density lipoprotein
(LDL) cholesterol >140 mg/dL. Diabetes mellitus was
deﬁned as HbA1c >6.5%, spot glucose >200 mg/dL, or
ongoing treatment with oral hypoglycemics and/or insulin
injections. Coronary artery disease (CAD) was deﬁned as
stable angina or a history of percutaneous coronary inter-
vention, coronary artery bypass graft surgery, or myocardial
infarction. Heart failure was deﬁned based on a history of
hospital admission for heart failure or current heart failure
symptoms. Aortic valve stenosis was deﬁned as more than
grade 3 severity measured by echocardiography. Cerebro-
vascular disease (CVD) was deﬁned as a history of stroke or
cerebral hemorrhage. Renal failure was deﬁned as an esti-
mated glomerular ﬁltration rate <30 mL/min/1.73 m2.
Chronic obstructive pulmonary disease (COPD) was deﬁned
as ongoing or previous treatment for COPD or FEV1 <70%
predicted. Anemia was deﬁned as hemoglobin <13 g/dL for
males and <11 g/dL for females. A Trans-Atlantic Inter-
Society Consensus (TASC) 2000 D classiﬁcation was deﬁned
as tibial or peroneal occlusions >2 cm or diffusely diseased
tibial or peroneal vessels. Below the knee runoff was
determined by digital subtraction angiography before EVT.
Statistical analysis
Data for the normal BMI (reference) group were compared
with those for the underweight and overweight/obese
groups. Continuous variables are reported as means with
standard deviation or medians with ﬁrst and third quartiles,
and are compared by unpaired t tests. Categorical variables
are shown as numbers with percentages and are compared
by the c2 test when appropriate or by Fisher’s exact test.
Event-free survival curves were calculated using the
KaplaneMeier method and compared by log-rank test.
Subgroup analysis was performed based on established
factors associated with mortality of patients with CLI to test
the interaction between BMI and other factors. The hazard
ratio (HR) and conﬁdence interval (CI) for independent
factors in Cox univariate analysis were calculated to deter-
mine suitability for inclusion in a Cox multivariate model(step-up procedure using the likelihood ratio). Factors with
p < .5 in univariate analysis were used in multivariate
analysis. Individual differences were considered to be sig-
niﬁcant at p < .05. All statistical analyses were performed
using commercial software (JMP version 10.0; SAS Institute,
Cary, NC, USA).
RESULTS
Patient and lesion characteristics
The characteristics of the patients are shown in Table 1. The
patients had a mean age of 72  10 years (range: 39e99
years). Underweight patients were more frequently female
and non-ambulatory; had higher rates of aortic valve stenosis
and Rutherford category 5 or 6; lower rates of hypertension
and diabetes; and lower levels of serum triglyceride and al-
bumin compared with patients with normal BMI. Over-
weight/obese patients had a higher prevalence of diabetes
and higher levels of triglyceride, and were also younger than
normal BMI patients. Among all 1088 patients, almost half
had CAD, 73% had diabetes mellitus (predominantly Type 2),
and 66% were in renal failure. The target lesions were mostly
TASC 2000 D grade and had poor below the knee runoff, and
70% were chronic total occlusions. There were no major dif-
ferences in lesion characteristics among the three groups
(Supplementary Table).
Causes of death
The median follow up period was 1.5 years (range: 1 month-
8.7 years); 35% (378/1088) of the patients died during this
period. All cause mortality in overweight/obese patients
was signiﬁcantly lower than that in patients with normal
BMI (23% [42/182] vs. 33% [238/718], p < .01), whereas
that of underweight patients was signiﬁcantly higher than
that in normal BMI patients (52% [98/188] vs. 33% [238/
718], p < .001). Cardiovascular death accounted for 38%
(142/378) of all deaths and this rate did not differ signiﬁ-
cantly among the groups. Infection accounted for 31% (119/
378) of all deaths and also did not differ signiﬁcantly among
the groups (Table 2).
Endpoints
Primary endpoints are presented as KaplaneMeier curves in
Fig. 2. The overall 3 year survival rates were 33.3%, 61.2%,
and 69.8% in underweight, normal BMI, and overweight/
obese patients, respectively. The rate was signiﬁcantly lower
in underweight patients and signiﬁcantly higher in over-
weight/obese patients compared with patients with normal
BMI (both p < .0001). Secondary endpoints are shown as
KaplaneMeier curves in Fig. 3. The rates for 3-year freedom
from MALE were 36.4%, 45.4%, and 52.3%, respectively, and
did not differ signiﬁcantly among the groups (p ¼ .32).
Subgroup analysis using Cox univariate and multivariate
analyses
No interaction was found that had an effect on multivar-
iate analysis of all cause mortality in subgroup analysis
Table 1. Patient characteristics according to BMI category.
BMI, kg/m2
All
(n ¼ 1088)
Underweight <18.5
(n ¼ 188)
Normal(Reference)
18.5 to 24.9 (n ¼ 718)
Overweight/obese 25
(n ¼ 182)
Patient characteristics
Age, yrs 72  10 73  9 72  10 68  10y
 80, n (%) 247 (23) 47 (25) 175 (24) 25 (14)y
Male, n (%) 756 (69) 117 (62)* 527 (73) 112 (62)y
Hypertension, n (%) 801 (74) 125 (66)* 534 (74) 142 (78)
Dyslipidemia, n (%) 452 (42) 64 (34) 299 (42) 89 (49)
Diabetes mellitus, n (%) 799 (73) 117 (62)* 533 (74) 149 (82)y
HbA1c (%) 6.3  1.5 5.9  1.3* 6.3  1.4 6.8  1.7y
>6.4e8.4 % 319 (29) 41 (22)* 215 (30) 63 (35)
8.4 % 105 (10) 11 (6) 63 (9) 31 (17)y
Insulin therapy, n (%) 321 (37) 39 (27)* 213 (38) 69 (45)
History of smoking, n (%) 384 (35) 61 (32) 261 (36) 62 (34)
CAD, n (%) 543 (49) 97 (52) 352 (49) 94 (52)
Heart failure, n (%) 218 (27) 42 (30) 141 (27) 35 (24)
Aortic valve stenosis, n (%) 91 (9) 24 (14)* 58 (9) 9 (5)
CVD, n (%) 257 (24) 38 (20) 185 (26) 34 (19)
Renal failure, n (%) 713 (66) 124 (66) 481 (67) 108 (59)
Hemodialysis, n (%) 669 (61) 117 (62) 452 (63) 100 (55)
COPD, n (%) 93 (9) 23 (12) 57 (8) 13 (7)
LDL-cholesterol (mg/dL) 91  32 88  32 91  32 97  32y
Triglyceride (mg/dL), median (25, 75%) 101 (77, 139) 89 (64, 118)* 102 (77, 140) 121 (85, 173)y
Serum albumin (mg/dL) 3.6  0.6 3.4  0.6* 3.6  0.6 3.6  0.6
<3.0 g/dL, n (%) 168 (15) 39 (21)* 105 (15) 24 (13)
Anemia, n (%) 770 (71) 143 (76) 518 (72) 109 (61)y
Hemoglobin <8.0 g/dL, n (%) 36 (3) 9 (5) 23 (3) 4 (2)
CRP (mg/dL) median (25, 75%) 0.8 (0.2, 3.1) 1.2 (0.4, 3.1) 0.7 (0.2, 3.0) 0.7 (0.2, 3.3)
>3.0 mg/dL, n (%) 274 (25) 49 (26) 178 (25) 47 (26)
Drugs
Aspirin, n (%) 860 (79) 138 (73) 572 (80) 150 (82)
Thienopyridine derivatives, n (%) 379 (35) 56 (30) 249 (35) 74 (41)
Cilostazol n, (%) 539 (50) 96 (51) 360 (50) 83 (46)
Anticoagulants, n (%) 222 (20) 43 (23) 152 (21) 27 (15)
Statins, n (%) 246 (23) 34 (18) 158 (22) 54 (30)
Beta-blockers n (%) 162 (20) 27 (19) 107 (20) 28 (19)
Lower limb characteristics
Non-ambulatory, n (%) 432 (40) 90 (48)* 282 (39) 60 (33)
Rutherford classiﬁcation
4 226 (21) 25 (13) 152 (21) 49 (30)
5 566 (52) 105 (56) 375 (52) 86 (47)
6 296 (27) 58 (31) 191 (27) 47 (26)
ABI
 0.9, n (%) 339 (33) 46 (26) 224 (33) 69 (39)
<0.4, n (%) 49 (5) 9 (5) 34 (5) 6 (3)
Underweight to normal (reference): *p < .05.Overweight / obese to normal (reference): yp < .05.
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with CLI (Table 3). Potential risk factors and HRs for
all cause mortality are shown in Table 4. Age, gender, BMI
<18.5 or >25 kg/m2, dyslipidemia, diabetes mellitus,
HbA1c, CAD, heart failure, aortic valve stenosis, CVD,
renal failure, hemodialysis, COPD, LDL-cholesterol, tri-
glyceride levels, serum albumin <3.0 g/dL, hemoglobin
<8 g/dL, C-reactive protein (CRP) >3.0 mg, medication
with anticoagulants or statins, non-ambulatory status,
Rutherford 5 or 6 classiﬁcation, and ABI >0.9 or <0.4
were signiﬁcant factors associated with overall survival. A
Cox multivariate model (step-up procedure using thelikelihood ratio) indicated that age, BMI <18.5 kg/m2,
heart failure, aortic valve stenosis, renal failure, triglycer-
ide level, serum albumin <3.0 g/dL, medication with an-
ticoagulants, non-ambulatory status, and a Rutherford 6
classiﬁcation were signiﬁcant factors associated with
overall survival.DISCUSSION
The major ﬁndings of this study are that (1) BMI has a
complex relationship with 3 year overall mortality in pa-
tients with CLI after EVT for isolated infrapopliteal artery
Table 2. Cause of death according to BMI category.
BMI, kg/m2
All (n ¼ 1088) Underweight <18.5
(n ¼ 188)
Normal (Reference)
18.5 to 24.9 (n ¼ 718)
Overweight/obese 25
(n ¼ 182)
All causes, n (%) 378 (35) 98 (52)* 238 (33) 42 (23) y
Cardiovascular death, n (%) 142 (38) 41 (42) 86 (36) 15 ( 36)
Myocardial infarction, n (%) 23 (6) 5 (5) 17 (7) 1 (2)
Heart failure, n (%) 69 (18) 22 (22) 41 (17) 6 (14)
Dysrhythmia, n (%) 15 (4) 5 (5) 7 (3) 3 (7)
Sudden death, n (%) 27 (7) 4 (4) 19 (8) 4 (9)
Aortic stenosis, n (%) 7 (2) 5 (5)* 1 (0.4) 1 (2)
Pulmonary embolism, n (%) 1 (0.2) 0 (0) 1 (0.4) 0 (0)
Cerebrovascular death, n (%) 19 (5) 3 (3) 10 (5) 6 (14) y
Cerebral infarction, n (%) 14 (4) 1 (1) 8 (3) 5 (12) y
Cerebral hemorrhage, n (%) 5 (1) 2 (2) 2 (0.8) 1 (2)
Other vascular death, n (%) 7 (2) 1 (1) 5 (2) 1 (2)
Nonvascular death, n (%) 209 (55) 53 (54) 136 (57) 20 (48)
Cancer, n (%) 20 (5) 6 (6) 13 (5) 1 (5)
Infection, n (%) 119 (31) 31 (32) 75 (32) 13 (31)
Sepsis, n (%) 73 (19) 14 (14) 50 (21) 9 (21)
Pneumonia, n (%) 38 (10) 16 (16)* 18 (8) 3 (10)
Other infection, n (%) 8 (2) 1 (1) 6 (3) 1 (2)
Gastrointestinal bleeding, n (%) 9 (2) 1 (1) 8 (3) 0 (0)
Others, n (%) 15 (4) 7 (7) 7 (3) 1 (2)
Unknown, n (%) 37 (10) 7 (7) 26 (11) 4 (10)
Sudden death: unobserved death that assumed to be related to a cardiovascular event.Underweight to normal (reference): *p <
.05.Overweight / obese to normal (reference): yp < .05.
Complex Relationship of Body Mass Index 301lesions; (2) this relationship was seen at 1 year follow up
and became clearer over time; and (3) underweight patients
with CLI have an extremely poor prognosis (overall 3 year
survival of 33.3%).
An overweight/obesity status has been associated with
development of cardiovascular disease in the generalFollow u
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Figure 2. KaplaneMeier curves for overall survival according to body ma
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survival rate was signiﬁcantly lower in underweight patients and signiﬁcpopulation and the prevalence has increased in recent
years.12 These conditions may also be associated with
excess cardiovascular mortality in long-term outcomes.13
Current guidelines for management of cardiovascular dis-
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Figure 3. KaplaneMeier curves for major adverse limb events (MALE) according to body mass index (BMI) category. The 3 year rates of
freedom from MALE were 36.4%, 45.4%, and 52.3% in the underweight, normal weight, and overweight/obese groups, respectively, and
did not differ signiﬁcantly among the groups (p ¼ .32).
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overweight and obese patients with established cardiovas-
cular disease have a more favorable long-term prognosis.1e
3 This relationship has also been found in patients with
peripheral arterial disease (PAD). Thus, Galal et al. followed
2392 patients with PAD after major vascular surgery, and
found a signiﬁcantly lower 4.4 year mortality in overweight
patients (HR 0.73; 95% CI 0.64e0.84) and obese patients
(HR 0.68; 95% CI 0.53e0.86) compared with underweight
patients (HR1.42; 95% CI 1.00e2.01).15 Other studies have
found similar results.4,5 However, this inverse association,
which has been termed the “obesity paradox,” has only
been linked to patients with claudication and those
requiring lower extremity revascularization or amputation.
Consistent with these results, the present ﬁndings show
a clear complex relationship between BMI and mortality in
patients with CLI. In the current study, patients with CLI
who had isolated infrapopliteal artery lesions and under-
went EVT as primary therapy were assessed. EVT for such
lesions is not inferior to bypass surgery in long-term out-
comes,16,17 but bypass surgery remains the ﬁrst line
treatment for revascularization in patients with CLI in
clinical practice. Physicians tend to select EVT for patients
with a poor general condition who are high risk for general
anesthesia. Therefore, the clinical characteristics in this
study were more complicated than those in previous
studies, including high rates of elderly patients (mean age
72  10 years; 23% octogenarians), non-ambulatory cases
(40%), and underlying diseases (heart failure 27%, coro-
nary artery disease 49%, cerebrovascular disease 24%).
Most patients also had diabetes (73%, predominantly Type
2), renal failure requiring hemodialysis (61%), and
complicated infrapopliteal artery lesions that wereocclusive and showed poor below the knee runoff on
angiography. Underweight patients comprised 17% of the
study population, whereas only 1% were obese. Interest-
ingly, this distribution is opposite to that in studies in
Western countries.4,7,8,15 The complicated clinical charac-
teristics may have contributed to the distribution in the
current study, in addition to ethnic differences. Kumakura
et al. found similar data in a Japanese cohort, in which
1.7% (11/652) of patients with PAD were obese,5 and thus
this distribution may be characteristic of Asian patients
with PAD.
Age (per 10-year increment), HR 1.22 (95% CI 1.07e
1.40); BMI <18.5 kg/m2, HR 1.58 (95% CI 1.17e2.14); heart
failure, HR 1.49 (95% CI 1.14e1.93); aortic valve stenosis,
HR 1.57 (95% CI 1.05e2.36); renal failure, HR 2.17 (95% CI
1.62e2.92); serum albumin <3 g/dL, HR 1.62 (95% CI 1.19e
2.20); medication with anticoagulants, HR 1.47 (95% CI
1.10e1.96); and non-ambulatory status, HR 2.26 (95% CI
1.73e2.96) emerged as negative factors associated with all
cause mortality in a Cox multivariate model. These pre-
dictors are similar to those found in previous studies, except
for anticoagulant therapy. Use of anticoagulants in patients
with renal failure (including those undergoing hemodialysis)
is controversial because of the increased risk of hemor-
rhage. The high prevalence of renal failure in the present
study may be related to this result. At the same time, tri-
glyceride levels (per 10 mg/dL) had a protective effect on all
cause mortality, HR 0.97 (95% CI 0.95e0.996). A previous
report5 showed a positive relationship between BMI and
triglyceride in patients with PAD. These authors suggested
that malnutrition, represented by low triglycerides, may be
a cause of increased risk in patients with lower BMI. This
ﬁnding accords with the present results.
Table 3. Subgroup analysis based on factors associated with
mortality of patients with CLI.
n HR 95 % CI p-value
Upper Lower
Total
Underweight 188 1.95 1.54 2.47 <.001
Normal 718 1.00 reference
Overweight/obese 182 0.66 0.47 0.91 .01
Age
Age < median
Underweight 81 1.89 1.33 2.70 <.001
Normal 350 1.00 reference
Overweight/obese 112 0.66 0.43 1.03 .07
Age  median
Underweight 107 2.01 1.47 2.76 <.001
Normal 368 1.00 reference
Overweight / obese 70 0.69 0.42 1.14 .145
Gender
Male
Underweight 117 2.11 1.56 2.85 <.001
Normal 527 1.00 reference
Overweight/obese 112 0.75 0.50 1.12 .16
Female
Underweight 71 1.66 1.12 2.45 .01
Normal 191 1.00 reference
Overweight/ obese 70 0.50 0.28 0.90 .02
Ambulatory Status
Non-ambulatory
Underweight 90 1.72 1.27 2.34 <.001
Normal 282 1.00 reference
Overweight/obese 60 0.86 0.55 1.32 .48
Ambulatory
Underweight 98 2.04 1.40 2.97 <.001
Normal 436 1.00 reference
Overweight/obese 122 0.60 0.36 0.99 .047
Albumin Level
<3.0 g/dL
Underweight 39 1.97 1.23 3.15 .005
Normal 105 1.00 reference
Overweight/obese 24 0.82 0.40 1.67 .59
 3.0 g/dL
Underweight 149 1.89 1.44 2.48 <.001
Normal 613 1.00 reference
Overweight/obese 158 0.64 0.44 0.93 .64
Heart failure
No
Underweight 99 1.95 0.40 2.71 <.001
Normal 391 1.00 reference
Overweight/obese 108 0.73 0.48 1.12 .15
Yes
Underweight 42 1.90 0.40 2.71 <.001
Normal 141 1.00 reference
Overweight/obese 35 0.41 0.20 0.85 .02
Aortic valves stenosis
No
Underweight 144 1.79 1.36 2.35 <.001
Normal 599 1.00 reference
Overweight/obese 164 0.62 0.43 0.88 .008
Yes
Underweight 24 2.03 1.12 3.68 .02
Normal 58 1.00 reference
Continued
Table 3-continued
n HR 95 % CI p-value
Upper Lower
Overweight/obese 9 0.86 0.30 2.48 .78
Renal failure
Yes
Underweight 124 1.97 1.51 2.59 <.001
Normal 481 1.00 reference
Overweight/obese 108 0.66 0.44 0.98 .04
No
Underweight 64 2.06 1.30 3.34 .003
Normal 237 1.00 reference
Overweight/ obese 74 0.81 0.45 1.47 .49
HR: hazard ratio, CI: conﬁdence interval
Complex Relationship of Body Mass Index 303Although BMI >25 kg/m2 was not signiﬁcantly associated
with mortality in the Cox multivariate model but was
signiﬁcantly associated with mortality in the Cox univariate
model, the KaplaneMeier curves and 0.73 of adjusted odds
ratio support BMI >25 kg/m2 as a possible positive pre-
dictor of survival.
The 3 year overall survival of normal weight patients was
61.2%, similar to that of 65% for all patients with CLI in a
recent meta-analysis. That of overweight/obese patients
was slightly higher (69.8%), whereas that of underweight
patients was extremely low (33.3%). This complex rela-
tionship between BMI and all cause mortality was seen at 1
year follow up and has become clearer over time. These
ﬁndings emphasize the markedly poor prognosis of under-
weight patients among all patients with CLI. Although un-
derweight patients had a higher incidence of severe
manifestations associated with mortality of patients with
CLI in their baseline characteristics (Table 1), subgroup
analysis showed a complex relationship of BMI with mor-
tality in all subgroups (Table 3), lessening the probability
that other differences in baseline characteristics had a large
impact. In contrast, freedom from MALE at 3 years did not
differ signiﬁcantly among the three groups.
The pathophysiology of the adverse effects of low BMI on
mortality is unclear. Death because of aortic valve stenosis
and pneumonia were signiﬁcantly higher in underweight
patients (Table 2), but all other causes of death did not
differ signiﬁcantly among the BMI categories. Increases in
both cardiovascular and non-cardiovascular death have
been reported in underweight patients with heart failure18
or coronary artery disease.19 Similar results were found in
patients with CLI, with most of the causes of death
becoming more frequent as BMI decreased. Several in-
vestigators20,21 have noted that the adverse effect of low
BMI on mortality is manifest only in patients with cardio-
respiratory failure. The high mortality in underweight pa-
tients with CLI who have severe systemic comorbidities and
poor general condition could be associated with very low
levels of cardiorespiratory failure. More than half of the
deaths in patients with CLI are reported to be caused by
cardiovascular events.6 In the present study, cardiovascular
events were the major cause of death, at 38%; followed by
infection, which had a notably high rate of 31%. These
Table 4. Cox univariate and multivariate (step-up procedure using likelihood ratio) analysis
n Univariate Multivariate
HR 95 % CI p-value HR 95 % CI p-value
Upper Lower Upper Lower
Age (per 10 yrs) 1088 1.18 1.07 1.31 .001 1.22 1.07 1.40 .004
Male (vs. female) 1088 0.90 0.73 1.12 .34 -
BMI
<18.5 kg/m2 1.95 1.54 2.47 <.001 1.58 1.17 2.14 .003
18.5 to 24.9 kg/m2 1.00 reference 1.00 reference
25 kg/m2 0.66 0.47 0.91 .01 0.88 0.59 1.32 .54
Hypertension 1088 0.96 0.76 1.20 .70 -
Dyslipidemia 1088 0.66 0.53 0.81 <.001 n.e.
Diabetes mellitus 1088 0.80 0.64 0.99 .04 n.e.
HbA1c (per 1 %) 1087 0.92 0.86 0.996 .04 n.e.
Insulin therapy 863 0.99 0.79 1.25 .94 -
History of smoking 1088 0.93 0.75 1.16 .52 -
CAD 1088 1.41 1.14 1.73 .001 n.e.
Heart failure 816 1.72 1.36 2.17 <.001 1.49 1.14 1.93 .003
Aortic valve stenosis 998 2.06 1.52 2.78 <.001 1.57 1.05 2.36 .03
CVD 1088 1.69 1.36 2.09 <.001 n.e.
Renal failure 1088 2.01 1.59 2.55 <.001 2.17 1.62 2.92 <.001
Hemodialysis 1088 1.97 1.57 2.47 <.001 n.e.
COPD 1088 1.85 1.35 2.52 <.001 n.e.
LDL-cholesterol (per 10 mg/dL) 1049 0.91 0.88 0.94 <.001 n.e.
Triglycerides (per 10 mg/dL) 1088 0.96 0.94 0.98 <.001 0.97 0.95 0.996 .02
Serum albumin <3.0 g/dL 1081 2.24 1.77 2.85 <.001 1.62 1.19 2.20 .002
Hemoglobin <8.0 g/dL 1082 2.19 1.38 3.47 .001 n.e.
CRP >3.0 mg/dL 1065 1.83 1.48 2.28 <.001 n.e.
Aspirin 1088 1.25 0.97 1.62 .09 n.e.
Thienopyridine derivatives 1088 0.83 0.67 1.03 .10 n.e.
Cilostazol 1088 0.92 0.75 1.12 .41 -
Anticoagulants 1088 1.54 1.23 1.94 <.001 1.47 1.10 1.96 .009
Statins 1088 0.68 0.52 0.89 .004 n.e.
Beta-blocker 824 1.19 0.90 1.58 .23 -
Non-ambulatory 1088 3.01 2.45 3.70 <.001 2.26 1.73 2.96 <.001
Rutherford classiﬁcation 1088
4 1.00 reference 1.00 reference
5 1.71 1,26 2,31 .001 1.13 0.77 1.68 .53
6 2.94 2.15 4.03 <.001 1.83 1.20 2.78 .005
ABI 1040
0.9 0.68 0.53 0.86 .002 n.e.
0.4e0.9 1.00 reference
<0.4 1.44 0.93 2.23 .10 n.e.
HR: hazard ratio, CI: conﬁdence interval, n.e.: number excluded by step-up procedure
304 N. Murata et al.results may be explained by the high prevalence of tissue
loss in the present cohort.Limitations
The study had a retrospective design despite use of a pro-
spectively maintained database. Also, the cohort excluded
patients with CLI who underwent bypass surgery or medical
therapy. Although there was an opportunity to recognize
patients with severe COPD because all the patients in this
study were treated in the hospital at least once, and a full
medical history was taken at that time, pulmonary function
tests were not performed in all patients, which may have
resulted in an underestimate of the prevalence of COPD
(9%) in the present study compared with previous studies.15
Classiﬁcation according to BMI is based only on weightrelative to height, and no data were available for body fat
distribution, such as waist circumference or waist to hip
ratio, which may be better predictors of cardiovascular
events. Also, changes in body weight over time were not
taken into account so the relationship of weight change
with outcomes remains to be elucidated.CONCLUSIONS
BMI was found to be related in a complex fashion to
mortality in patients with CLI who underwent EVT for iso-
lated infrapopliteal artery lesions. This relationship was
observed at 1 year follow up and became clearer over time.
Underweight patients with CLI had an extremely poor
prognosis compared with those of normal BMI and over-
weight/obese patients with CLI. Underweight patients with
Complex Relationship of Body Mass Index 305CLI had many factors associated with mortality, but low BMI
emerged as a novel independent predictor of a poor
prognosis.
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